MIRA PHARMACEUTICALS, INC. — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
MIRA Pharmaceuticals announced positive results from a 21-day preclinical study of MIRA-55, an oral synthetic cannabinoid analog, in a chronic inflammatory pain model using 72 rats. MIRA-55 demonstrated statistically significant pain reduction (p<0.001 vs. vehicle) comparable to celecoxib (Celebrex) at higher doses, with sustained efficacy over three weeks without observed tolerance, reduced inflammation-associated swelling, and favorable tolerability (no adverse signs). The company plans to submit an Investigational New Drug (IND) application in Q1 2027, with Ketamir-2 also advancing toward Phase 2 for neuropathic pain.
Why this rating
Preclinical proof-of-concept for lead program is meaningful for $16M company, de-risks path to IND filing. Positive but early-stage; clinical success unproven.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.